In Brief This Week: Illumina; Accelerate Diagnostics; Massachusetts Life Sciences Center | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina this week declared conformity with the requirements of the IVD Directive and has applied the CE mark for the MiSeqDx Cystic Fibrosis System. It added that it is finalizing plans to launch the product in "a number" of European countries that require CE marking. The system comprises Illumina's MiSeq benchtop next-generation sequencing instrument, two assays — the MiSeqDx Cystic Fibrosis Diagnostic Assay and the MiSeqDx Cystic Fibrosis Carrier Screening Assay — and associated software. The system is available for order in Europe beginning this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.